The U.S. Food and Drug Administration has approved Verastem's combination therapy for patients with a rare type of ovarian ...

The U.S. Food and Drug Administration has approved Verastem's combination therapy for patients with a type of ovarian cancer ...

US FDA approves Verastem’s Avmapki Fakzynja combo therapy to treat patients with KRAS-mutated recurrent low-grade serous ovarian cancer: Boston Saturday, May 10, 2025, 13:00 Hrs ...

Matthew Herper joins Adam and Allison to examine Prasad’s appointment and the band of outsiders now in charge of U.S. health ...

In its 15th year, Verastem Oncology has gained its first FDA approval, winning an accelerated nod for the combination ...

The US Food and Drug Administration (FDA) has granted accelerated approval to Verastem Oncology’s oral combination therapy ...

The Avmapki Fakzynja Co-Pack marks the first FDA-approved treatment for adult patients with KRAS-mutated recurrent low-grade ...

The US Food and Drug Administration (FDA) has approved Avmapki Fakzynja Co-pack (avutometinib capsules; defactinib tablets) ...

Boston-based Verastem Oncology on Thursday won accelerated approval from the FDA for Avmapki Fakzynja as a second-line ...

The FDA has granted accelerated approval to Avmapki (avutometinib) plus Fakzynja (defactinib) for the treatment of KRAS-mutated, recurrent low-grade serous ovarian cancer.

FDA approves the first treatment for KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC), offering new hope for ...

The FDA has granted accelerated approval to the combination therapy of avutometinib and defactinib (Avmapki Fakzynja Co-pack) ...